AbbVie Stock Price, News & Analysis (NYSE:ABBV)

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie announced a -- dividend on Monday, September 9th. Shareholders of record on Tuesday, October 15th will be paid a dividend of $1.07 per share on Friday, November 15th. This represents a yield of 6.4%. The ex-dividend date is Friday, October 11th. View AbbVie's Dividend History.

AbbVie announced that its Board of Directors has initiated a stock repurchase plan on Thursday, December 13th 2018, which permits the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 3.8% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's board believes its stock is undervalued.

AbbVie Inc (NYSE:ABBV) released its quarterly earnings data on Friday, July, 26th. The company reported $2.26 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.05. The company earned $8.26 billion during the quarter, compared to analyst estimates of $8.09 billion. AbbVie had a net margin of 12.62% and a negative return on equity of 182.70%. The firm's revenue was down .3% on a year-over-year basis. During the same period in the previous year, the business posted $2.00 earnings per share. View AbbVie's Earnings History.

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, November 1st 2019. View Earnings Estimates for AbbVie.

AbbVie will be holding an earnings conference call on Friday, November 1st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

AbbVie issued an update on its FY19 earnings guidance on Friday, July, 26th. The company provided earnings per share guidance of $8.82-8.92 for the period, compared to the Thomson Reuters consensus estimate of $8.78.

14 brokerages have issued 1-year target prices for AbbVie's stock. Their predictions range from $66.61 to $115.00. On average, they expect AbbVie's stock price to reach $85.38 in the next twelve months. This suggests a possible upside of 9.8% from the stock's current price. View Analyst Price Targets for AbbVie.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 6 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AbbVie.

News stories about ABBV stock have trended somewhat positive recently, according to InfoTrie. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AbbVie earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for AbbVie.

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX), Valeant Pharmaceuticals Intl (VRX) and Toronto-Dominion Bank (TD).

AbbVie's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Robeco Institutional Asset Management B.V. (0.20%), Rhumbline Advisers (0.16%), Envestnet Asset Management Inc. (0.09%), PGGM Investments (0.08%), State of New Jersey Common Pension Fund D (0.08%) and Hamlin Capital Management LLC (0.07%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

ABBV stock was sold by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, State of New Jersey Common Pension Fund D, Park National Corp OH, CWM LLC, Bowling Portfolio Management LLC, Security National Bank, Gateway Investment Advisers LLC and Decatur Capital Management Inc.. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Brian L Durkin, Henry O Gosebruch, Laura J Schumacher, Richard A Gonzalez, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

ABBV stock was acquired by a variety of institutional investors in the last quarter, including PGGM Investments, Miller Howard Investments Inc. NY, Alberta Investment Management Corp, Robeco Institutional Asset Management B.V., Candriam Luxembourg S.C.A., Commerzbank Aktiengesellschaft FI, TIAA FSB and Rhenman & Partners Asset Management AB. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin and William J Chase. View Insider Buying and Selling for AbbVie.

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ABBV stock can currently be purchased for approximately $77.75.

AbbVie has a market capitalization of $114.95 billion and generates $32.75 billion in revenue each year. The company earns $5.69 billion in net income (profit) each year or $7.91 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.View Additional Information About AbbVie.

The official website for AbbVie is http://www.abbvie.com/.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.